Scancell Company

Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Technology: DNA, Atrificial Vectors and Immune Cells, Peptides and Proteins
Industry: Covid-19
Headquarters: Nottingham, Nottingham, United Kingdom
Founded Date: 1996-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 5
Total Funding: 245000000
Estimated Revenue: Less than $1M
Last Funding Date: 2016-08-04
Last Funding Type: Post-IPO Equity

Visit Website
scancell@fticonsulting.com
https://www.twitter.com/scancellpharma
Register and Claim Ownership